Nanjing Yufang Biotechnology

Nanjing Yufang Biotechnology is a clinical-stage biopharmaceutical company based in Nanjing, China, focused on the discovery and development of innovative small molecule therapeutics. The company leverages its expertise in targeted protein degradation (TPD), including PROTAC technology, to address unmet medical needs in oncology and metabolic diseases. Its lead candidate, YF-001, is a next-generation selective estrogen receptor degrader (SERD) currently being evaluated in clinical trials for the treatment of ER-positive, HER2-negative advanced breast cancer. Yufang Bio aims to develop highly potent and selective oral degraders that overcome resistance to existing endocrine therapies. The company is led by a management team with significant experience in global drug discovery and is backed by leading life science investors.